Michelle Avery

Michelle Avery is our SVP of Corporate Affairs. She brings over a decade of strategic leadership in corporate communications, investor relations, and patient engagement across public and private biotech companies. 

She previously served as SVP of Corporate Affairs at Tome Biosciences, a biotechnology company developing CRISPR-based large genomic insertion DNA engineering platform technologies. Prior to joining Tome, Michelle was Senior Director of Investor Relations at Pandion Therapeutics, which was acquired by Merck in 2021. 

Michelle earned her PhD in neuroscience from UMass Chan Medical School and holds a BA in neuroscience and dance from Skidmore College.